Navigation Links
Therapeutic DNA Vaccine Company Inovio Biomedical Reports Second Quarter 2008 Financial Results
Date:8/7/2008

vestment advisor informed us that decreased market liquidity for this type of security caused the valuation of these investments to fall below par. At June 30, 2008, we recorded on our consolidated balance sheet an unrealized loss of $1.1 million on these investments and reclassified $12.5 million as a non-current asset.

These securities retain the AAA/AA ratings they had when we purchased them, and have yielded uninterrupted interest payments that we receive on a monthly basis directly from the issuers. The lack of liquidity may require us to hold the ARSs until they are redeemed by the issuer or to maturity, but we believe the decline in their liquidity and fair value is temporary. We expect that liquidity of these investments is not required to fund our operations during the next twelve months. The Company anticipates receiving approval of and executing a $5.0 million line of credit from its investment advisor in the third quarter, secured by the ARS, to provide additional working capital.

Corporate Update

The operational highlights for the second quarter included further positive interim results reported by our partners from ongoing DNA vaccine clinical studies. A summary of these results follows, covering R&D and clinical studies using Inovio's electroporation delivery technology. More details can be found in the news release section of Inovio's website.

The University of Southampton presented interim data from its phase I/II clinical study of an experimental DNA-based prostate cancer vaccine, indicating that the combination of this DNA vaccine and electroporation DNA delivery was safe and well-tolerated. Patients treated using electroporation displayed higher levels of antibody and cellular immune responses. Data from preclinical studies performed in collaboration with scientists at Beth Israel Deaconess Medical Center (BIDMC) demonstrated a 77-fold increase in dendritic cells at the site of administration of a D
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Stiefel Laboratories Completes Acquisition of Barrier Therapeutics
2. Nektar Therapeutics Announces Second Quarter 2008 Results
3. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
4. InteKrin Therapeutics Announces $20 Million Series C Financing
5. Transition Therapeutics Announces No Material Change
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on August 8
7. DIA/AAPS Co-Sponsored Conference to Examine the Immunogenicity of Therapeutic Proteins
8. Cell Therapeutics, Inc. Announces $12 Million Equity Line of Credit
9. Stiefel Laboratories, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period Relating to its Proposal to Acquire Barrier Therapeutics, Inc.
10. Neurotherapeutics presents special issue on new treatments for Alzheimers disease
11. Horizon Therapeutics Names Timothy P. Walbert as President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Therapeutic DNA Vaccine Company Inovio Biomedical Reports Second Quarter 2008 Financial Results 
Therapeutic DNA Vaccine Company Inovio Biomedical Reports Second Quarter 2008 Financial Results
(Date:12/4/2009)ANAHEIM, Calif., Dec. 4 Pamela Bowen, Chief Information Officer at Crescent Healthcare, was selected as a finalist for the "Chief Innovation Officer" Appy Award for transforming Crescent,s business w
(Date:12/4/2009)WASHINGTON, Dec. 4 In response to the U.S. Justice Department Drug Enforcement Agency,s (DEA) classification of boldione, desoxymethyltestosterone, and 19-nor-4,9(10)-androstadienedione as "anabolic
(Date:12/4/2009)STANFORD, Calif. A new study shows that muscle cells grown in the lab can restore an intestine,s ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat pa
(Date:12/4/2009)Case Western Reserve University researchers, from the School of Medicine,s Department of Nutrition, discovered two new metabolic pathways by which products of lipid peroxidation and some drugs of abus
(Date:12/4/2009)Rockville, MD "Why is it that men can be bastards and women must wear pearls and smile?" wrote author Lynn Hecht Schafran. The answer, according to an article in the Journal of Vision , may lie in
Breaking Medicine News(10 mins):Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2Health News:Natural Products Association Issues Statement on DEA's Steroid Classification Action 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2Health News:Are angry women more like men? 2
... Houston-based Law Firm Offers Assistance...bri Effects. , Houston, T...awyers Pulaski & Middleman announce the launch...abri (natalizumab)., , ,Tysabri, a drug used to tr...
...1 The federal Centers for,Disease Control and Pre...of,annual new cases of HIV infections will be reve... of the American Medical Association (JAMA). The,r... revised estimate for 2006 will replace the curren...
...th glioblastoma multiforme (GBM), one of the most ... poor prognosis. Although pre-clinical studies ind... known as receptor tyrosine kinases (RTKs) would l...to such treatment and most subsequently relapse af...
..."convenience to home or work" as the main reason t... recent study conducted by researchers at the Univ...t Center in Cincinnati, OH. , The study included...y C. Mahoney, MD, lead author of the study. , Th...
...g. 1 Veridex, LLC announced today it,has complete...ially all of,the assets of Immunicon Corporation (...sidiaries., The assets acquired include intellect...ate the detection and enumeration,of circulating t...
...PRNewswire-FirstCall/ - Transition Therapeutics In... TSX:TTH) reports today that,there are no undisclo...olving the Company to account for its recent chang...ions with large markets. Transition,s lead,product...
Other Medicine News:Health News:Tysabri Lawyers Pulaski & Middleman Launch Web Resource Center for Patients Suffering from Tysabri Side Effects 2Health News:Estimate of Annual HIV Incidence Increases Significantly; New Estimate Will Show Need For a National AIDS Strategy 2Health News:Estimate of Annual HIV Incidence Increases Significantly; New Estimate Will Show Need For a National AIDS Strategy 3Health News:Transition Therapeutics Announces No Material Change 2
(Date:12/3/2009)WILMINGTON, Del., Dec. 3 ParagonRx, a Delaware-based company specializing in pharmaceutical risk management and optimal medication use, will host a free webinar on Wednesday, Dec. 9, on the FDA,s dra
(Date:12/3/2009)FORT WORTH, Texas, Dec. 3 Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), a rapidly growing provider of specialty medical products, announced today an agreement with the Health In
(Date:12/3/2009)COSTA MESA, Calif., Dec. 3 TROY Group, Inc., a Worldwide Leader in Secure on-Demand Printing Solutions, announces the addition of the TROY 3015 SecureRx(TM) Printer to its line of secure prescripti
Breaking Medicine Technology:Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up 2Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up 3New TROY SecureRx Prescription Printer Marks 50th Hospital Installation Milestone 2MediciGlobal Wins Four International 2009 Communications Awards for Patient Recruitment and Retention 49256 1MediciGlobal Wins Four International 2009 Communications Awards for Patient Recruitment and Retention 49256 2Texas Institute for Surgery at Presbyterian Hospital of Dallas Introduces the First Wireless OR in DFW 49253 1Texas Institute for Surgery at Presbyterian Hospital of Dallas Introduces the First Wireless OR in DFW 49253 2National Minority Quality Forum to Release Groundbreaking National HIV AIDS Atlas 49249 1National Minority Quality Forum to Release Groundbreaking National HIV AIDS Atlas 49249 2
...nt Infusion Study in Patients with,Chronic Decompe...lege of Cardiology 56th Annual Scientific Session ...5, 2007,/PRNewswire/ -- Scios Inc. announced today...f nesiritide (NATRECOR(R)) showed a,neutral effect...,cardiorenal hospitalization at 12 weeks, and prov...
... Technology Holds Promise as,Future-Generation Tre...h Coronary Artery Disease, ABBOTT PARK, Ill., Marc...announced positive results from ABSORB, the world,...ty and performance,of a fully bioabsorbable drug- ...ry artery disease. Six- month results from the,fir...
Other Medicine Technology:Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 2Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 3Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 4Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 5Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 6Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 7Abbott Announces Positive Six-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent 2Abbott Announces Positive Six-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent 3
Lap Disc Hand Access Device
SleepStyle 232
ResMed S7™ Lightweight CPAP Device
REMstar Pro with C-Flex
Medicine Products: